06086.HK
Fangzhou Inc.
HKSE · Consumer Cyclical · Drug Manufacturers - General · CN
HKD 0.72
+2.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.7B | 3.5B | 2.7B | 2.4B | 2.2B |
| Cost of Revenue | 5.7B | 3.0B | 2.2B | 1.9B | 2.1B |
| Gross Profit | 1.1B | 559.4M | 515.9M | 487.4M | 441.2M |
| Operating Expenses | |||||
| R&D Expense | 57.0M | 36.3M | 41.6M | 41.5M | 61.8M |
| SG&A Expense | 1.1B | 550.2M | 1.3B | 374.5M | 507.9M |
| General & Admin Expense | 288.4M | 147.3M | 909.5M | 92.4M | 177.5M |
| Selling & Marketing Expense | 778.9M | 401.2M | 355.8M | 343.8M | 330.2M |
| Other Expenses | (24.2M) | (40.5M) | (13.2M) | 123.2M | 72.4M |
| Total Operating Expenses | 1.1B | 546.0M | 1.3B | 539.3M | 642.1M |
| Cost and Expenses | 6.7B | 3.5B | 3.5B | 2.5B | 2.5B |
| Operating Income (EBIT) | (5.3M) | 13.4M | (777.7M) | (51.9M) | (261.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | (68.9M) | 1.4M | 2.2M | 1.6M | 1.2M |
| Net Interest Income | (3.0M) | (1.4M) | (2.2M) | (1.6M) | (1.2M) |
| Other Non-Op Income/Expense | (14.4M) | (1.4M) | (77.2M) | (144.8M) | (121.8M) |
| Non-Operating Income (excl Interest) | (20.7M) | 903.0K | (33.6M) | 143.2M | (134.7M) |
| EBT (Pre-Tax Income) | (19.7M) | 12.0M | (854.9M) | (196.7M) | (383.3M) |
| Income Tax Expense | (4.3M) | 194.0K | 32.0K | 77.0K | 13.0K |
| Bottom Line | |||||
| Net Income | (15.4M) | 11.8M | (854.9M) | (196.8M) | (383.3M) |
| Earnings from Cont. Ops | (15.4M) | 11.8M | (854.9M) | (196.8M) | (383.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.4M) | 11.8M | (854.9M) | (196.8M) | (383.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.01) | HK$0.01 | (HK$0.88) | (HK$0.26) | (HK$0.69) |
| Diluted EPS | (HK$0.01) | HK$0.01 | (HK$0.88) | (HK$0.26) | (HK$0.69) |
| Revenue Per Share | HK$4.91 | HK$2.65 | HK$2.77 | HK$3.27 | HK$3.41 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.3B | 975.9M | 744.8M | 646.4M |
| Diluted Shares Outstanding | 1.4B | 1.3B | 975.9M | 744.8M | 646.4M |
| Profitability Metrics | |||||
| EBITDA | 14.8M | 16.0M | (739.9M) | (174.8M) | (123.0M) |
| D&A | 7.3M | 3.5M | 4.2M | 20.3M | 3.8M |
| EBIT | 15.3M | 12.5M | (744.1M) | (195.1M) | (126.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026